|
|
|
|
Дата |
|---|
| 06.08.2026 |
| 05.08.2026 |
| 04.08.2026 |
| 03.08.2026 |
| 02.08.2026 |
| 30.07.2026 |
| 29.07.2026 |
| 28.07.2026 |
| 27.07.2026 |
| 26.07.2026 |
Bid | Ask |
Open |
Min | Max |
Last |
Legal close |
Avg |
Оборот |
Кол-во сделок |
|---|---|---|---|---|---|---|---|
|
|
|
130.00
|
128.01
|
137.70
|
130.05
|
|
|
796 415 619.38
|
11 647.00
|
|
|
|
134.30
|
127.27
|
141.90
|
130.00
|
|
|
679 587 905.09
|
12 539.00
|
|
|
|
149.76
|
132.12
|
156.00
|
134.30
|
|
|
1 032 846 674.46
|
17 553.00
|
|
|
|
124.80
|
141.06
|
149.76
|
149.76
|
|
|
1 030 467 133.53
|
15 953.00
|
|
|
|
104.00
|
104.20
|
124.80
|
124.80
|
|
|
343 604 437.90
|
5 344.00
|
|
|
|
96.50
|
95.75
|
104.88
|
104.00
|
|
|
464 787 383.01
|
7 219.00
|
|
|
|
93.40
|
93.40
|
97.89
|
96.50
|
|
|
262 933 869.94
|
5 397.00
|
|
|
|
92.80
|
92.85
|
94.79
|
93.40
|
|
|
93 811 777.79
|
2 129.00
|
|
|
|
90.10
|
92.10
|
97.90
|
92.80
|
|
|
343 267 047.27
|
6 401.00
|
|
|
|
91.50
|
90.01
|
93.50
|
90.10
|
|
|
49 930 593.04
|
1 679.00
|
Период |
|---|
| 2025, регулярные |
| 2022, регулярные |
| 2020, регулярные |
| 2018, регулярные |
| 2017, регулярные |
| 2016, регулярные |
| 2015, регулярные |
| 2012, регулярные |
| 2011, регулярные |
| 2010, регулярные |
|
Экс-дивидендная дата
|
Закрытие реестра |
Сумма выплаты |
|---|---|---|
|
26.04.2026
|
27.04.2026 |
3.5 EGP |
|
13.04.2023
|
18.04.2023 |
2 EGP |
|
21.04.2021
|
25.04.2021 |
2.95 EGP |
|
02.05.2019
|
05.05.2019 |
4 EGP |
|
06.04.2018
|
10.04.2018 |
4.5 EGP |
|
08.05.2017
|
09.05.2017 |
3.5 EGP |
|
21.04.2016
|
24.04.2016 |
3.5 EGP |
|
23.04.2013
|
24.04.2013 |
3 EGP |
|
24.05.2012
|
27.05.2012 |
3 EGP |
|
29.04.2011
|
02.05.2011 |
2.5 EGP |
Egyptian International Pharmaceuticals Industries Co SAE (EIPICO) is an Egypt-based public shareholding company that operates in the pharmaceuticals industry. The Company is a manufacturer and exporter of pharmaceuticals, and holds license agreements with a group of international pharmaceutical companies to produce their products locally and replace the imported ones. The Company produces dosage forms, such as spansule capsules (long-acting), as well as non-traditional dosage forms, such as the soft gelatin capsules, lyophilized products, gels, sprayers and effervescent tablets
